Ying–Hong Shi

机构：Zhongshan Hospital, Ministry of Education · ORCID：0000-0002-1833-8988

发表论文 336 篇 · 总被引 17094 次 · h-index 58

代表论文

• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 45)
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 41)
• Metabolism archetype cancer cells induce protumor TREM2+ macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma (2025 · Nature Communications · 被引 31)
• Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells (2025 · Signal Transduction and Targeted Therapy · 被引 16)
• FTO downregulation-mediated m6A modification resulting in enhanced hepatocellular carcinoma invasion (2025 · Cell & Bioscience · 被引 12)
• Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity (2025 · JCI Insight · 被引 12)